Hennion & Walsh Asset Management Inc. Grows Stock Holdings in uniQure N.V. $QURE

Hennion & Walsh Asset Management Inc. grew its position in shares of uniQure N.V. (NASDAQ:QURE) by 107.3% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 142,113 shares of the biotechnology company’s stock after buying an additional 73,566 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in uniQure were worth $6,546,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Kalehua Capital Management LLC purchased a new stake in uniQure in the 1st quarter worth approximately $4,760,000. UBS Group AG increased its stake in shares of uniQure by 139.7% during the fourth quarter. UBS Group AG now owns 491,454 shares of the biotechnology company’s stock valued at $11,760,000 after buying an additional 286,465 shares during the period. Voss Capital LP raised its holdings in shares of uniQure by 68.0% during the fourth quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company’s stock valued at $5,025,000 after acquiring an additional 85,000 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of uniQure by 37.2% during the fourth quarter. Jennison Associates LLC now owns 1,371,190 shares of the biotechnology company’s stock valued at $32,813,000 after acquiring an additional 371,706 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in uniQure in the fourth quarter worth $2,764,000. 78.83% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Walid Abi-Saab sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the transaction, the insider directly owned 148,235 shares of the company’s stock, valued at approximately $6,881,068.70. This represents a 16.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the sale, the director owned 43,254 shares in the company, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 388,229 shares of company stock worth $16,817,099 over the last three months. 4.65% of the stock is currently owned by insiders.

uniQure Stock Performance

Shares of uniQure stock opened at $46.42 on Monday. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The firm’s 50-day moving average is $39.41 and its 200 day moving average is $27.07. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of -11.58 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same period last year, the firm posted ($0.69) earnings per share. Sell-side analysts anticipate that uniQure N.V. will post -3.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on QURE shares. Mizuho boosted their price objective on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Chardan Capital increased their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Wells Fargo & Company raised their target price on uniQure from $60.00 to $75.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Royal Bank Of Canada increased their price target on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Finally, Barclays lowered their price target on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday, July 30th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $65.00.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.